Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Angel Rodriguez Sanchez"'
Autor:
María P. Fernandez‐Perez, Enrique Perez‐Navarro, Teresa Alonso‐Gordoa, Vicenza Conteduca, Albert Font, Sergio Vázquez‐Estévez, Aránzazu González‐del‐Alba, Daniel Wetterskog, Emmanuel S. Antonarakis, Begona Mellado, Ovidio Fernandez‐Calvo, María J. Méndez‐Vidal, Miguel A. Climent, Ignacio Duran, Enrique Gallardo, Angel Rodriguez Sanchez, Carmen Santander, Maria I. Sáez, Javier Puente, Julian Tudela, Alberto Martínez, Maria J. López‐Andreo, José Padilla, Rebeca Lozano, David Hervas, Jun Luo, Ugo de Giorgi, Daniel Castellano, Gerhardt Attard, Enrique Grande, Enrique Gonzalez‐Billalabeitia
Publikováno v:
The Prostate. 83:376-384
Background There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). Methods We conducted a phase II trial of enzalutamide in first-line chemo-na
Autor:
A. García-Palomo, Mariana López-Flores, Ana Lopez-Gonzalez, Carmen Castañón-López, Maria Luisa Garrido Onecha, Blanca Tavara Silva, Amaya Lanz Lozano, Mariam Rojas Piedra, L.F. Sánchez-Cousido, Angel Rodriguez Sanchez
Publikováno v:
Oral Oncology. 118:2
Autor:
L.F. Sánchez-Cousido, Pilar Diz Taín, Beatriz Nieto Mangudo, Ana Lopez-Gonzalez, Amaya Lanz Lozano, Luis Miguel de Sande, Mariana López-Flores, Angel Rodriguez Sanchez, Andrés García-Palomo, Carmen Castañón-López
Publikováno v:
Oral Oncology. 118:3
Autor:
A. García-Palomo, Amaya Lanz Lozano, L.F. Sánchez-Cousido, Mariam Rojas Piedra, Carmen Castañón-López, Ana Lopez-Gonzalez, Blanca Tavara Silva, Mariana López-Flores, Angel Rodriguez Sanchez
Publikováno v:
Oral Oncology. 118:4
Autor:
Eric Jonasch, Luca Dezzani, Chaitali Babanrao Pisal, Angel Rodriguez Sanchez, Yulia Hirschberg, Giuseppe Procopio, Haralabos P. Kalofonos, Narayanan Srihari, Manuela Schmidinger, Cristina Suarez Rodriguez, Qasim Ahmad, Aristotelis Bamias, Sergio Vázquez Estevez, Petri Bono, Robert E. Hawkins
Patients with intermediate-risk advanced renal cell carcinoma are a heterogeneous population, having either 1 or 2 risk factors. It is unclear whether all patients in this risk category should be treated similarly. A secondary analysis of the PRINCIP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b57f3a70bfd6fbe312985080127fd42d
http://hdl.handle.net/10138/318789
http://hdl.handle.net/10138/318789
Autor:
Albert Font Pous, Begoña Mellado, Angel Rodriguez Sanchez, Miguel Angel Climent, Maria Jose Mendez, Enrique Gallardo, Ovidio Fernandez Calvo, Gerhardt Attard, Natalia Fernández Núñez, Carmen Santander, Daniel Castellano, Vincenza Conteduca, Ignacio Duran, Enrique Grande, M Isabel Sáez, Javier Puente, Daniel Wetterskog, Enrique Gonzalez-Billalabeitia, Aranzazu Gonzalez del Alba, Maria Piedad Fernandez Perez
Publikováno v:
Journal of Clinical Oncology. 35:5016-5016
5016 Background: Building on previous discoveries studying AR status in plasma (Carreira S, Sci Transl Med 2014, Romanel A, Sci Transl Med 2015) and following a road-map for biomarker development, we aimed to clinically qualify AR status in chemother
Autor:
M.L. Romero Bogado, M. Άlvarez-Mon, P. Pretel Ruiz, Angel Rodriguez Sanchez, A. Movasat, A. Pérez Gόmez, D. Clemente Garulo, Cristina Bohórquez, A. Turriόn Nieves, Fernando Albarrán, Eduardo Cuende, H. Moruno-Cruz, J.C. Lόpez Robledillo
Publikováno v:
Annals of the Rheumatic Diseases. 75:1199.1-1199
Background Biologic drugs are a mainstay in the treatment of juvenile idiopathic arthritis (JIA). The early use of these drugs allows controlling disease activity avoiding its consequences and improving the quality of life of patients. We know the ma
Autor:
Rocío García Domínguez, Enrique Gonzalez-Billalabeitia, María José Méndez-Vidal, Laura Basterrechea, Antonio López Jiménez, Alvaro Pinto, Carmen Molins, Núria Sala, Raquel Luque, Angel Rodriguez Sanchez, Pablo Borrega, Jose Miguel Cuevas Sanz, Guillermo Crespo, Montserrat Domenech, Sergio Vazquez-Estevez, Javier Puente, Josep Guma, Pedro Ruiz, Aranzazu Gonzalez del Alba, Miguel Ángel Cabrera Suárez
Publikováno v:
Journal of Clinical Oncology. 34:229-229
229 Background: Novel agents, such as abiraterone (A), cabazitaxel (CZ), and enzalutamide are currently available for the treatment of docetaxel (D)-treated metastatic castration resistant prostate cancer (mCRPC). The sequencing approach following D
Autor:
Ángel Rodríguez Sánchez
La obra presenta la historia singular de una delación colectiva provocada por el poder. A finales del XVI los habitantes de Coria se vieron obligados, por mandato de su obispo, a realizar una confesión sobre los vicios y malas costumbres de ellos m
Publikováno v:
LLULL : boletin de la Sociedad Espanola de Historia de las Ciencias. 25(54)